Novo Nordisk has been made aware of some Ozempic® and Saxenda® pens in Uzbekistan, Azerbaijan and Kazakhstan that have been falsified and are not legitimate. The falsified products have been sold both within the legal and illegal supply chain. The content of the falsified pens is entirely different from the genuine products and should not be used as the falsified pens pose a risk to patients’ safety.
The main difference between the counterfeit product and the genuine product is that the genuine Novo Nordisk Ozempic® and Saxenda® pens do not extend or increase in length when setting the dose. The scale drum increments are fixed doses, such as 0.25 mg, 0.5 mg, and 1.0 mg for Ozempic® and 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg and 3.0 mg for Saxenda®.
A falsified pen can be identified based on scale going from 0 to 80 units and extending out from the pen when setting the dose.
Patient safety is a top priority for Novo Nordisk and we are in close dialogue with all relevant stakeholders to support patients in the best possible way against falsified products.
If you have any questions, please contact firstname.lastname@example.org or call +998 78 120 66 55.
Please click here to go directly to our internal career site to view all our current job openings.
Here are our current job openings. If there is not a job you are looking for, you are welcome to create a job agent or a candidate profile.